Publications by authors named "Jordan Clark"

Orthohantaviruses are emerging zoonotic viruses that can infect humans via the respiratory tract. There is an unmet need for an in vivo model to study infection of different orthohantaviruses in physiologically relevant tissue and to assess the efficacy of novel pan-orthohantavirus countermeasures. Here, we describe the use of a human lung xenograft mouse model to study the permissiveness for different orthohantavirus species and to assess its utility for preclinical testing of therapeutics.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research indicates that both neutralizing and non-neutralizing antibodies can help protect against severe COVID-19, even when non-neutralizing antibodies don’t directly neutralize the virus.* -
  • Non-neutralizing antibodies may recruit immune cells to help clear infected cells and often bind to virus parts that are conserved across different variants.* -
  • The study analyzed 42 human monoclonal antibodies from vaccinated individuals, finding that some non-neutralizing antibodies can provide protection in animal models, highlighting their potential role in immunity.*
View Article and Find Full Text PDF

Neurological complications, including encephalopathy and stroke, occur in a significant proportion of COVID-19 cases but viral protein is seldom detected in the brain parenchyma. To model this situation, we developed a novel low-inoculum K18-hACE2 mouse model of SARS-CoV-2 infection during which active viral replication was consistently seen in mouse lungs but not in the brain. We found that several mediators previously associated with encephalopathy in clinical samples were upregulated in the lung, including CCL2, and IL-6.

View Article and Find Full Text PDF

Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how vaccines specifically designed for the Omicron XBB.1.5 variant can generate effective B-cell responses, focusing on the antibody responses in individuals who received a monovalent vaccine.
  • Researchers analyzed immune responses from 603 plasmablasts, expressing 100 human monoclonal antibodies to assess their effectiveness against various SARS-CoV-2 variants.
  • Two specific monoclonal antibodies, M2 and M39, were identified; M2 targeted only XBB.1.5 while M39 could neutralize both XBB.1.5 and JN.1, highlighting the functional potential of variant-specific vaccines.
View Article and Find Full Text PDF
Article Synopsis
  • - COVID-19, caused by SARS-CoV-2, can worsen when combined with influenza viruses, leading to increased health risks in infected individuals.
  • - Research using mice showed that sequential infection with influenza A and SARS-CoV-2 resulted in more severe symptoms, including quicker weight loss and greater lung damage, compared to single infections.
  • - Interestingly, prior vaccination with a live-attenuated influenza vaccine can reduce SARS-CoV-2 replication without worsening disease severity, indicating that certain immune responses may help combat COVID-19.
View Article and Find Full Text PDF

SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation plays a major role. This is reminiscent of the process commonly termed cytokine storm, a condition dependent on a disproportionated production of cytokines. This state involves the activation of the innate immune response by viral patterns and coincides with the biosynthesis of the biomass required for viral replication, which may overwhelm the capacity of the endoplasmic reticulum and drive the unfolded protein response (UPR).

View Article and Find Full Text PDF
Article Synopsis
  • - Recent studies reveal that while neutralizing antibodies are important for protection against SARS-CoV-2, binding antibodies without strong neutralizing activity can still help prevent disease progression by potentially recruiting immune cells to clear infected cells.
  • - Researchers characterized 42 human monoclonal antibodies (mAbs) from vaccinated individuals, finding that many lacked neutralizing activity but still provided protection in animal models against severe infections.
  • - The study's findings support the real-world observation that non-neutralizing antibodies targeting specific regions of the virus can offer protection, emphasizing the importance of both types of antibodies in the immune response to SARS-CoV-2.
View Article and Find Full Text PDF

Louping ill virus (LIV) is a tick-borne flavivirus that predominantly causes disease in livestock, especially sheep in the British Isles. A preventive vaccine, previously approved for veterinary use but now discontinued, was based on an inactivated whole virion that likely provided protection by induction of neutralizing antibodies recognizing the viral envelope (E) protein. A major disadvantage of the inactivated vaccine was the need for high containment facilities for the propagation of infectious virus, as mandated by the hazard group 3 status of the virus.

View Article and Find Full Text PDF

Fundamental approaches to the study of groundwater rely on investigating the spatial and temporal distribution of stable and radioactive isotopes and other anthropogenic compounds in natural waterbodies. The most often used tracers for estimating groundwater flow paths and residence times, groundwater/surface water interaction as well as tracing chemical (contamination) sources include stable isotopes of water (δ O and δ H), radiocarbon (C; t = 5730 a), tritium (H; t = 12.43 a) as well as unreactive fluorine-containing gases (e.

View Article and Find Full Text PDF

To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1-11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury.

View Article and Find Full Text PDF

The respiratory system is the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 19 (COVID-19) where acute respiratory distress syndrome is considered the leading cause of death. Changes in pulmonary blood vessels, among which an endothelialitis/endotheliitis has been particularly emphasized, have been suggested to play a central role in the development of acute lung injury. Similar vascular changes are also observed in animal models of COVID-19.

View Article and Find Full Text PDF

Myosin heavy chain 9 (MYH9) has been identified as a crucial factor in gammaherpesvirus infection. Murine gammaherpesvirus 68 (MHV-68) was used as an appropriate viral model for investigating gammaherpesviruses in vivo and developing antiviral treatments. However, the roles of MYH9 in MHV-68 infection have not been documented.

View Article and Find Full Text PDF

Background: Monkeypox virus has recently infected more than 88 000 people, raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side-effects than previous smallpox vaccines and has shown immunogenicity against monkeypox in animal models. This study aims to elucidate human immune responses to JYNNEOS vaccination compared with mpox-induced immunity.

View Article and Find Full Text PDF

Background: Precision oncology medicines represent a paradigm shift compared to non-precision oncology medicines in cancer therapy, in some situations delivering more clinical benefit, and potentially lowering healthcare costs. We determined whether employing a companion diagnostic (CDx) approach during oncology medicines development delivers effective therapies that are within the cost constraints of current health systems. R&D costs of developing a medicine are subject to debate, with average estimates ranging from $765 million (m) to $4.

View Article and Find Full Text PDF

Aim: The aim of this evaluation was to assess the impact of introducing a model of Trauma-Informed Care (TIC), comprising weekly Power Threat Meaning Framework (PTMF) Team Formulation and weekly Psychological Stabilisation staff training, to a National Health Service (NHS) adult acute inpatient mental health unit over a four-year period.

Method: A retrospective service evaluation design was employed to assess for differences in the number of incidents of self-harm, seclusion and restraint in the four-year period following the introduction of TIC, when compared to the year prior.

Results: Significant reductions were demonstrated in the monthly number of incidents of self-harm ( < 0.

View Article and Find Full Text PDF

Winter presents a challenge for survival, yet temperate ectotherms have remarkable physiological adaptations to cope with low-temperature conditions. Under recent climate change, rather than strictly relaxing pressure on overwintering survival, warmer winters can instead disrupt these low-temperature trait-environment associations, with negative consequences for populations. While there is increasing evidence of physiological adaptation to contemporary warming during the growing season, the effects of winter warming on physiological traits are less clear.

View Article and Find Full Text PDF

Background: Mpox (formerly known as monkeypox) outbreaks outside endemic areas peaked in July 2022, infecting > 85,000 people and raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side effects than previous smallpox vaccines and demonstrated efficacy against mpox infection in humans. Comparing JYNNEOS vaccine- and mpox-induced immunity is imperative to evaluate JYNNEOS' immunogenicity and inform vaccine administration and design.

View Article and Find Full Text PDF

Seasonal coronaviruses have been circulating widely in the human population for many years. With increasing age, humans are more likely to have been exposed to these viruses and to have developed immunity against them. It has been hypothesized that this immunity to seasonal coronaviruses may provide partial protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it has also been shown that coronavirus disease 2019 (COVID-19) vaccination induces a back-boosting effects against the spike proteins of seasonal betacoronaviruses.

View Article and Find Full Text PDF

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a complex strategy for the transcription of viral subgenomic mRNAs (sgmRNAs), which are targets for nucleic acid diagnostics. Each of these sgmRNAs has a unique 5' sequence, the leader-transcriptional regulatory sequence gene junction (leader-TRS junction), that can be identified using sequencing. High-resolution sequencing has been used to investigate the biology of SARS-CoV-2 and the host response in cell culture and animal models and from clinical samples.

View Article and Find Full Text PDF

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) not only affects the respiratory tract but also causes neurological symptoms such as loss of smell and taste, headache, fatigue or severe cerebrovascular complications. Using transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2), we investigated the spatiotemporal distribution and pathomorphological features in the CNS following intranasal infection with SARS-CoV-2 variants, as well as after prior influenza A virus infection. Apart from Omicron, we found all variants to frequently spread to and within the CNS.

View Article and Find Full Text PDF
Article Synopsis
  • The Omicron variant of SARS-CoV-2 was first discovered in November 2021 in South Africa and has quickly spread worldwide, outpacing the Delta variant in many areas.
  • Omicron contains a large number of mutations in its spike protein, leading to increased transmissibility and reduced vaccine effectiveness, especially in convalescent or double-vaccinated individuals.
  • Research shows that while immune responses (like virus-neutralizing activity) are lower against Omicron compared to the original virus, those who have had multiple exposures through vaccination and infection mostly retain some level of immunity.
View Article and Find Full Text PDF

SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration.

View Article and Find Full Text PDF

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has triggered a worldwide health emergency. Here, we show that ferritin-like Dps from hyperthermophilic Sulfolobus islandicus, covalently coupled with SARS-CoV-2 antigens via the SpyCatcher system, forms stable multivalent dodecameric vaccine nanoparticles that remain intact even after lyophilisation. Immunisation experiments in mice demonstrated that the SARS-CoV-2 receptor binding domain (RBD) coupled to Dps (RBD-S-Dps) elicited a higher antibody titre and an enhanced neutralising antibody response compared to monomeric RBD.

View Article and Find Full Text PDF